QuidelOrtho Corporation

QDEL

US2197981051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
34.85 ^USD	+2.05%		+16.32%	-52.71%

24/06	RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	MT
05/06	QuidelOrtho Seeks Inorganic Options	CI

Quidel Corporation Announces Revenue Guidance for the Fourth Quarter of 2019

January 10, 2020

Quidel Corporation announced that it expects revenues in the fourth quarter of 2019 to be in the range of $151 million to $152 million.

Latest news about QuidelOrtho Corporation

RBC Cuts Price Target on QuidelOrtho to $61 From $68, Keeps Outperform Rating	24/06	MT
QuidelOrtho Seeks Inorganic Options	05/06	CI
Transcript : QuidelOrtho Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 01:20 PM	05/06
QuidelOrtho Opens New Distribution Center in Pedricktown, NJ	16/05	CI
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	15/05	RE
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	15/05	MT
Jana Partners Acquires Stake in QuidelOrtho	14/05	MT
Activist Jana Partners built position in QuidelOrtho in first quarter, sources say	14/05	RE
RBC Cuts Price Target on QuidelOrtho to $68 From $81, Keeps Outperform Rating	09/05	MT
Tranche Update on QuidelOrtho Corporation's Equity Buyback Plan announced on August 17, 2022.	09/05	CI
Transcript : QuidelOrtho Corporation, Q1 2024 Earnings Call, May 08, 2024	09/05
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Posts Q1 Revenue $711M, vs. Street Est of $695.1M	09/05	MT
Earnings Flash (QDEL) QUIDELORTHO CORPORATION Reports Q1 EPS $0.44, vs. Street Est of $0.40	09/05	MT
QuidelOrtho Corporation Suspends Earnings Guidance for the Year 2024	09/05	CI
QuidelOrtho Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
QuidelOrtho Corporation Announces CEO Changes	02/05	CI
QuidelOrtho Corporation Appoints Brian J. Blaser as President and to the Board	02/05	CI
QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay	02/04	MT
QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test	02/04	MT
QuidelOrtho Corporation Receives FDA 510(K) Clearance for its QuickVue COVID-19 Test	02/04	CI
QuidelOrtho Receives Canada's Approval for Triage PLGF Test to Detect Pregnancy Complications	07/03	MT
Transcript : QuidelOrtho Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 04:00 PM	06/03
Sector Update: Health Care Stocks Mixed Late Afternoon	05/03	MT
Sector Update: Health Care	05/03	MT
QuidelOrtho Shares Decline Following UBS Downgrade	05/03	MT

QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.

Sector

Advanced Medical Equipment & Technology

Calendar

01/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for QuidelOrtho Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

34.85 USD

Average target price

50 USD

Spread / Average Target

+43.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
QUIDELORTHO CORPORATION	-52.71%	233.4Cr
SARTORIUS AG	-26.08%	1.66TCr
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+14.25%	182.46Cr
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.87%	139.86Cr
BIOTAGE AB	+39.87%	147.14Cr
REVENIO GROUP OYJ	+6.33%	84Cr
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-29.23%	81Cr
CONTEC MEDICAL SYSTEMS CO.,LTD	-37.71%	71Cr
VAREX IMAGING CORPORATION	-28.00%	60Cr
CELLAVISION AB	+32.78%	62Cr

Medical Diagnostic & Testing Equipment

QuidelOrtho Corporation

Equities

QDEL

US2197981051

Advanced Medical Equipment & Technology

Quidel Corporation Announces Revenue Guidance for the Fourth Quarter of 2019

Latest news about QuidelOrtho Corporation

Chart QuidelOrtho Corporation

Company Profile

Income Statement Evolution

Ratings for QuidelOrtho Corporation

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Medical Diagnostic & Testing Equipment